Date: December 11, 2024
Time: 8:00 AM (PST), 11:00 AM (EST), 5:00 PM (CET)
Keynote Presentation: Precision Diagnosis of Ovarian Cancer – Identification of Protein Biomarkers that Separate Benign from Malignant Tumors
Ulf Gyllensten, Senior Professor at the Department of Immunology, Genetics and Pathology, Uppsala University
Ovarian cancer has the highest mortality among gynecological cancers, with surgery often used for final diagnosis. Accurate molecular tests are needed when imaging techniques are inconclusive. We analyzed 5416 plasma proteins in two cohorts of women with benign or malignant ovarian tumors. In the discovery cohort, we compared protein levels of benign tumors with early (I-II), late (III-IV), or any stage (I-IV) ovarian cancer. We identified 327 associations involving 191 unique proteins, with 326 (99.7%) replicating in the second cohort. Only 11% (21/191) of these proteins showed significant correlation with tumor gene expression levels. Protein-protein correlation networks revealed that 62 proteins were highly correlated with at least one other protein, indicating many associations are secondary effects. Multivariate models trained on the discovery cohort, using a fixed cut-off for malignancy, achieved an AUC of 0.96 in the replication cohort, with 97% sensitivity at 68% specificity. For early-stage tumors, sensitivity was 91% at 68% specificity, compared to 85% and 54% for CA-125 alone. Our findings suggest that plasma protein levels do not necessarily correlate with tumor gene expression, and an 8-protein panel could significantly reduce the need for diagnostic surgery in suspected ovarian cancer cases.
Live Q&A will follow the presentation
Discover True Biological Insights with the Accuracy of Olink Explore HT
We will discuss the accurate path to finding new biology with Olink Explore HT and share technical details on the library's power, the robustness of the PEA assays, and the platform's accuracy. If you have technical questions on the Explore HT solution, come with them for the final live discussion.
Key Learning Objectives
- Learn how plasma protein analysis differentiates benign from malignant ovarian tumors Discover how analysing plasma protein levels can distinguish between benign and malignant ovarian tumors with high sensitivity and specificity.
- Assess the potential of protein biomarkers to enhance early-stage cancer detection Explore how a targeted protein biomarker panel achieves higher diagnostic accuracy compared to traditional markers, particularly in early-stage cases.
- Evaluate the effectiveness of the Olink Explore HT platform in accelerating biomarker discovery Understand the technical features that make it the solution of choice for biomarkers identification and profiling
Webinars will be available for unlimited on-demand viewing after live event.